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card*ac anomatios ~,~ cunently unknown, isolated LVNC has been shown to 
occur with X.linked inhentanco and mutations in the taffazin (G45) gone and 
protein The purpose of th~s teporl is to desenba the ¢1in¢~1 findings of LVNC 
with VSD in two children which suggest a possible etiology different from that 
of iSO!a|(~ LVNC 
M~tf~:  TwO neonates who prosentnd with heart taduro were identified 
by echoc~lrdiography as hawng LVNC with associated VSD Subsequent 
clintc,~l work-up employed the Pediamc Cardiomyop~thy RegistW diagnos- 
tm a~nlhm which included evaluation o! serum el~rolytes, eamltine and 
aolt-eamitiea profiles, aotl.CeA dehydfogenases, serum am,no acids, unne 
organic acids, and skeletal muscle I~opsy, with of without endomyocardtat 
b~psy, for hislology, e!O~-'tron mzcfos¢opy (EM), msl~mtory chain enzyme 
analysis, and mitochondtial DNA (mtDNA) mutation screen 
Re.~ulP3. In both patlenls (2 female~) skelefa! muscle biopSy demonstr~t ~) 
abnolma! mltt~bendnal nund~er a!~! ~ppeam~ by histology and EM (one 
patient) bad intran.tochondnal inctusions), consistent with e mitochonclnal 
proliferative d~sea~lo+ Enzyme stainin~ Showed a r~J~++ticn of cytochrom~ 
omdase. No mutabons in G45 were Identified. Analysis for mtDNA mut-llons 
IS currently tmderway 
Conctusmn: LVNC wffh V$13 is assooeted with abnormal m~tochondna 
and m, tochondna! resp~ralely chain abnormatibes. Tbemfore, LVNC appears 
to be frenetically hEterocjeneous. Sl:~Clhc mtDNA mutations respenmble for 
the chscrder am 13elqg sought 
I 1014-160] Outcome of Infantile Familial Dilated 
Cardlomyopathy. Comparison With the 
Non-fami l ia l  D isease  in Pediatr ic Age Group 
M A. Set/am. K.B. Manasra, M. Pahleo. ARAMCO Dhahran Hea#h Center. 
Dhahran, Sauo~ Arabia 
O ~ :  TO desc~nbe the natural h~ston/of famdial Idiopathic D=alated Car- 
ckomyopathy (IDCM) presenting in intatqcy and to compare its clinical course 
w~th the non-famdlal form of IDCM 
Bac~gn~und: Familial eh~togy of IDCM has been reported repeatedly 
among (bfferent age groups. The outcome of this dmhnct form of IDCM when 
presents exclusively in inta~:y has not b~on descnbed. 
Methods; Four famdms with a total of 17 cases of IDCM who presented 
before two years ol age are the focus of this study. Each fam, ly has at least 3 
affected sibhngs. No~e of the~e petmnts (Pts.) has any co~:jenrtal or acquired 
head dF~ease. The ctin¢cal CouP3e of these mfant~ was compared wr~ that of 
38 ~ v e  children wdh IDCM 
Echo~rdiogrephy was the main modal~,, for chagnosis and follow-up 
None of these Pts. underwent heart transplantation Medical therapy was the 
only treatment offered. 
Re~ul~s All cases of fami!ial InCM presented before 2 years of age Four- 
leon ut mere u~eo a;.;c ~r-tore 2 yea~ of age ttctal modality 88<'=) There 
was no difference boh'.'een these famd~al cases and non-farad=at ones =n sex 
dcstnbubon, age at diagnoszs, location o! referral, preceding viral mfect~on. 
echocard=ograph~c LV shortening fraction on presentation, conventional drug 
therapy, usage of steroids. }.-globulins or B-Blockers. Acute IV inotropics and 
long term vasoddators were used much more in familial cases (P = 003 ano 
0.006 respectively). The rnalor difference between the two groups, however. 
was sun/ival; 2~17 (12%) among familial cases versus 28/38 (74%) of non- 
familial cases. P - 0.0001. Among non-familial cases. LV systolic function 
returned to normal in 37% ot the cases ~,~thin 6 months of presentahon and 
remained abnormal in 37% of them up to the latest follow up. 
Conc/usrons: Familial IDCM (30% of IDCM cases in our pediatnc popu- 
lation) carnes a very poor prognosis when presents in infancy. Heart trans. 
plantation (H. Tx,) should be considered as soon as possible once diag- 
nosis is made. The non-tamilial disease has 74% probability of survival 
Therefore aggressive medical therapy should be attempted before H. Tx. is 
sought. 
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~ Ventricular in Patients With Dilated Funct ion  
Card iomyopathy  is Improved by VDD Pacing at  
Left but  Not  R ight  Ventr icu lar  Sites 
D.A. Kass, C.-H. Chert, B. Fetics, M. Talbot. E. Nevo. M. Nakayama. Johns 
Hopkins Unwersi~ Baltimore MD. USA 
Background: Ventncular pre-excitahon by VDD pacing with a shod AV delay 
is a potential therapy for patients with dilated heart failure (DCM). However. 
th0 optrmat paczng szto may not I~ 1~o nghl ventnculat apex ~s ,s mostly 
w~G~ely employ(~l 
MethOcl~: Cardiac c~thatonzatlon by pressure-volume an~lys~s wa~ per, 
formed in 14 pts with DCM (NYHA.II!-!V. me~lrt EF 19 .~ 2%i Base!ins QR$ 
and PR .ntervals were t47 ~ g 2 ms and 207 ~ 21 ms, respeettvety VDD 
I:~lcm9 was perfon/~d with activation at the RV apex (RVA), rf~d RV septum 
(RVS), LV base (LV~, vi~ coroea~ veno~s p~ctng wire), of b~,~ntn¢~r (RVA 
* LV) Steady.state d~t~ measured pnof to and t ~2 mm a~et the onset of 
pacing were recorded 
Results: Only VD_O p~c,n~ I at the LVB induce(~ slgn!f~..ant changes m LV 
syslotic function, if~|e~ti!~l by a n,~e In peak pressure (Psys) ar~ m~L~k,~al 
pressure (~nvative (d~/dt~,) 
FIVA RV~ LVB RVA * LV 
Psys 27 ~ 20 (~7 ~ 09 73 t 1 t 'tr 23 ,- I 7 
Datalr~tai~heare%~% i e, emfromsmusm~thmNSR.',p, O001veNSR t p, 00t 
vsRVA ! -p 001 vsR~S 
Results with biventncutaf pacing were worse than wrlh single-site LV 
pacing PV loops obtruded in a subset of patients were consistent with these 
(~la. The contractile response to pacing s~gncfmantly correlated w~th baseline 
ORS duration (p = 0.00~), mdcatmg the importance of electro-mechanical 
a~:tivatio. ¢~,;.~y lu tim re,~po~,se 
Conctusmns. VDD pacing can substantmlly =mprove LV systolic functlon 
~n DCM patients, but this effect depends upon the site of actwatlon, LV pacing 
m preferable over RV or bwenmcular pacing 
• Cl in ica l  and Object ive improvements  in Severe 
Congest ive  Heart Fai lure Pat ients Using 
Univentricular or Blventricular Pacing: 
Preliminary Results of a Randomized Prospective 
Study 
A. Auncch~o. C. 3tel:bnnk. M Block, P Modensen. On Dehalf of the 
PATH-CHF fnvest~gators: Unevetsdy Hospital Magc/eburg. Germany 
I ~ n ;  Prewous non-randomized studms evaluating pacing therapy in 
severe congestive heart failure (CHF) have reported conflicting results. The 
"PATH-CHF" (PAcing THerapy in CHF) study is a prospestwe mu~center 
study companng umventncular (Urn), i.e. right (RV) or lefl ventncular (LV) 
s~mulabon, to bnrentncular (BN) paong in patients (pts) with severe CHF 
Matt.:/s: After implant of 2 pacemakers, each pt was randomized m a 
cross-over study, including 4 weeks of Um pacing and 4 weeks o! RN pacing 
separated by a wash-out penod Optimal Um pacmg mode and AV delays 
were selected by extensive mtraoperatwe test 
Results. The study included 16 pts with @lated congestwe cardtomyopathy 
of any ongl=, stable NYHA Ill/IV. PR mten~al • 150 ms and ORS duration 
• 120 ms. Mean age was 59 ~ 5 yrs. Mean LV elation fraction was 22 ± 7% 
Changes in NYHA class, quality-of-life tOOL), 6-minute walking test (6-mm), 
maximal work rate (WR) and VO2 at anaerobic threshold (AT VO~) are listed 
below 
Pre-lmplant Um BIV p varue 
NYHA 33:03  15~05 14=04 -0001 
QOL (Mlnnesc, ta score) 54 .- 16 25 = 22 12 = 15 ~ 0001 
6-m.,n (m) 295=61 375=106 410 ~ 64 -001 
WR tWans) 62 ++ 21 92 : 42 90 ~ 40 - 0 05 
AT VO2 t mL kg.,rnm) 90 :13  117t25 134~25 -005 
P values re|el5 to comparison between !)m +3rid BIV ,..s Pre-fn~t~tt~ 
Conclusions: These data demonstrate significant short-term objectrve ,m- 
provement dunng Um or B~V pacing in selected CHF pts. Long.term foflow-up 
will allow confirmation of these early findings. 
i1015-31 i Excellent Effect on Left Ventrlcular Despite an J Performance, Carvedilel Falls to Improve the 
Pulmonary Function and Peak Exercise 02 
Uptake  in Chronic Heart Failure. Any  Link? 
M GuazzL P.G. Agostoni. N. TtLm,qsi. M.D. Guazzi. Institute of Cardtolog~ 
University of Mdan. CN R . Mdan. Italy 
Background: Disturbances in ventilation and in pulmonary gas transfer (stress 
failure of alveolar-capillary membrane) due to chronic head fadure (CHF). 
participate in limiting peak exercise oxygen uptake (pVO2). This study was 
aimed at investigating the effects of carvedilol on lung function in CHF. as ~t 
improves left ventdcular dysfunction and not pVO2 
Methods: 21 NYHA class I1-111 pabents given digoxin and furosem~de. 
were randomized (two t'~ one) to ca~,~ilol (25 mg I0 d !4 pts) or placebo (7 
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pts) for 6 months. Rest forced expiratory volume (FEV~), vital capacity (VC), 
total lung capacity (TLC), carbon monoxide diffusing capacity (DLco), its alve. 
olaf-capillary membrane component (DM), pulmonary venous and trensmitral 
flow velocitlel~ (for monitoring changes in LV and.diastolic pressure, EDP). left 
ventrlcular end.dlastolic (EDD) and end,systolic (ESD) dimensions, stroke 
volume (SV), ejection fraction (EF), fiber shodenlng velocity (Vcl) were mea- 
sured at baseline, 3 end 8 months, pVO=, peak dead epees to tidal volume 
ratio (pVDNT). ventllefory equivalent for CO;z production (VENCO=), VO~ at 
anaerobic threshold (VO~at) wore also determined, 
Result=: Compared with 14 healty voluntssr~. FEV~, VC, DLco, DM were 
Impalrod In CHF and did not Improve with carvadllol, It slgnlfleantty reduced 
LVEDP, BOB, BeD, and Increased SV, El=, Vcf but failed to ameliorate pVO~, 
VO~at. oVDNT. VENCO~ Placebo was not effective, Data at 3 and 6 months 
Cor~lu~/on~: Lack of pulmonary function Improvement desphe excellent 
amelioration at left ventrlculer function, suggs~lS the development in CHF of 
an Irreversible or slow reversible organio lung dleoase, or a need for phsrma. 
¢oioglcl~l pr0pedlss that carvedliol does not ponose, Persistent pulmoneP/ 
dysfunction may prevent pVO~ Improvement, 
• t ,ong,tefm Survive! lEft, at of in Dilated Metoprolo!  
Cardlomloplthy 
A, DI Len~rd~, R, DO M~rla, A, Gave=el, D, Gmgorl, M, ParotlnL G, S;insgra, 
L, ~lvstom, F, Long,m, E Bomoblch. F, CamortnL Oep~rtmenf at 
Caedtoto~, ~e;  Iat~f~ dt Fisiologl~ C/mica CNR, Mil~no, linty 
8~Ckl~0Un~: Although meloproiol (M) Is olfactlvo In dilated el~rdiomyop~thy 
(IDC), ~ontfolled ata am lacking on long term survival We evaluated the 
a~ect of M on long.term survival in 58~ pts with IDC. prospectively enrolled 
in a mufflcentsr registry and followed up for 52 t 32 months, M, uptttrated to 
the ma~lmum lolerated dose, was added to conventional therapy in 175 of 
them1 
R~ults: Soven,yo~r survtvel (8t% vs 60%, p .~ 0,0001) and transplant, 
free survival (69% w 49%, p ,= 0,0004) were higher In the 175 M.treatod 
pts 1hen in the 411 on standard treatment, By multivariate anatysls. M was 
as#colored to a 5t% redqetion for all.cause modallty (95% CI ~21 to 69%, 
p ,~ 0,00~) and a 34% for mortality or lransplentation (95% CI 5 to . 53%, p 
- 0,01), NYHA class, LV end diastolic diameter and palmonary wedge pros, 
sure w~l~ likewise predictive. Seven-year survival (80% v 62%, p ® 0,0036) 
and transplant-free suwlvat (68% v 51%, p = 0,0053) wore also higher in 
127 M,tmated cases than in 12"/controls, appropriately matched for key 
prognostic variables. Mpts showed a 30% reduction in all.cause mortality 
(98% CI to 48%, p = 0,0147) and a 26% reduction in mortality or 
transplantation (95% CI 7% to 41%, ~ = 0,0009), 
Conch~io~,~: The addition el metoprelol tO standard therapy, including 
ACE-tnhibltors, was effective in the long.term, reducing both all cause mor- 
tality and trnnsplant~tion mpatients with IDC, 
~ Beta,Blocker Therapy In Patients With Clinical 
Evidence o! Heart Failure After Acute Myocardial 
Infarction 
C,S, Spatulas, A,S, Hall, S,G, Ball. Institute for Cardiovascular Research, 
Unimrsity or Leeds, IlK 
B,'~ckground: Clinical evidence of congestive heart failure (HF) after acute 
myocardia! infarction (MI) is considered by many to be a contralndlcation to 
p-adrenergtc blockade, Furthermore, there is uncertainty as to the value of 
these agents following routine use of aspirin, thrembolytlc and ACE,inhibiter 
therapy, We examine clinical outcomes associated with optional to-blockade 
in a post MI population with evidence of HI=, 
Methods: We retrospectively analyzed data from the AIRE study (ran- 
domized, placebo-controlled trial of ramipril in 2006 post MI patients with 
clinical evidence of HF), At baseline, 20% o! the patients were receiving a 
t~-blocker, Diuretic treatment at randomization defined a high risk group with 
poorer left ventricular function (LVF). To eliminate confounding, we sepa- 
rately analyzed patients according to diuretic use, adjusting for the presence 
of multiple clinical signs of HF and 15 other baseline clinical variables. Each 
was simultaneously entered in a multivariate Cox regression model. 
Results: t~-blocker therapy was a significant independent predictor of 
reduction in the risk of all-cause mortality (34%. CI 10% to 51%, p .-:. 0,008) 
and severe HF t43%, C118 to 60%, p = 0.002) for the entire study population, 
Similar findings occurred in high risk patients receiving diuretic (39%, C110% 
to 58%, p = 0.012; 42%, CI 11% to 62%, p = 0.013) but not in those not 
requiring diuretic use (19%, CI -38 to 53%, NS; 41%, CI - 17% to 70%, NS). 
Conclusion: Our data indicate that in the modem era/~-blocker therapy 
benefits patients with clinical evidence of HF post MI. 
• Evidence Against Heart Rate Reduction aa the 
Primary Mechanism of  Act ion of  Carvedllol  In 
Chronic  Heart Failure 
J.D. Sockner.Bornateln, MIA, Lakes, B, Wu. For the U.S, Carvedilol 
InveBflgMOPa: Columbia Unlverel~ College of Physicians & Surgeorw New 
York, USA 
Carvedilol (CV) reduaee morbidity and modallty and Improvn quality of life 
In patients with head failure (HF). A mochanletio reid of hoed rata reduction 
(AHR) has been postulated, We evaluated the relationships betwoen the 
/~HR by CV and Its Iong.tam~ clinical and leR vQntdcular eff~"ts. 
Patients enrolled In the US tflats who received ¢awedllOI for their dou- 
ble.blind therapy were evaluated (n = 690), Moat had NYHA Iblll e/mpfoml, 
and mean ej~tion fraction (EF) was 0.23. CV was started at 6,25 mg BID 
and tltrated to 25.-50 mg BID over 4-,6 w~kll. ,~HR was ~l~lBted from 
the difference botween heed rates pdor Io and altQf titration, Logls~ m- 
gmseion was podormed to determine If ,.~HR wee re la~ to 1) progree,ldon 
el HF, 2) global assessment by physician and I~tlent, 3) ANYHA ¢!au, 4) 
Asympfom stalus, and 5) AEF PotioNs w~m divided by the n~dian ~HR 
with coml~aon ot outcome variable, 
~HR t'~ormlated signifimantly but weakly with ANYHA and ~I~F (r ~. 0,08, 
p ,= 0,03 and r ~ 0,15, p ~ 0,003, respe4:tively), Patients with the greatest 
AHR did not have a different clintoai out,=oma, 
,~HR door nat correlate strongly with the long.term effects of CV. Nauro, 
hormonal antagonism tndebendent of chronofm4~iQ effects m~y be the poman/ 
me(~hanism of benefit, The degree at ~,HR should not be the drama! 1elliot 
when treating patients with earvediiol, 
Eff~t of Carvedllol on Symptom 8¢om in Heart 
. . . .  Failure 
EM, Oilbml, M,A, Lukes, S, Wu, M,B, Fowler, For the US Carve~lol Hem1 
~ilure Study Group: Univen~ty of Utah. Salt Lake Cilg, UT, USA 
Patients (pts) in the US Carvedilol (C) Head Failure (HF) Tt~ls Program 
randdmi~ed to placebo (P, n ,= 398] or C (n = 698) had HF oymptoms 
assessed by a quantitative score of fatigue and of dyspnea (met, walking 
on level ground and climbing stairs) by a scale ot 0 (none) to 3 (severe). 
PIe' well,being was rated by a scale of 0 (YeW good) to 3 (Pcof)- Malimum 
possible overall score was 0-21, 
Results: Table o! within and between group (P vs C) changes at endpoint: 
Analyzed by baseline sevedty (submaxtmal exercise intoleraoceL overall 
Score improved on C vs P by 1,3 (p ~ 0.01), 0,5, and 1,8 (p = 0,10) in pts 
with mild, moderate or severe impairment, respectively. 
Question BL AP BL AC ,'~P vs C 
Ovoratl 8 4 063 8 3 1 27 0 64" 
Dyspnea-rest 0 5 0 04 0 5 0 04 O 08"" 
Dyspnea,level I I  O15 1.1 0 .17  00~ 
Dyspnea,stairs 1.? -0 18 1.7 -0.24 006 
Fatigue-i~st 00 ,0,07 08  ,0.11 0.04 
Fatigue.level 1.1 ~ 0 02 1.1 - O. 18 O, 16" 
Fatigue.eta(re 1 6 -.0.09 1,7 - 0.27 0.181 
Pts well,being 1 S Q.17 1.5 026 009 t 
• p = 0,Of:" p = 0,08: t p = 0003: t p = 0.09 [eL = t~sellno], 
Conclusion: Analyzed using a quantitative heart failure symptom score, 
canmdilol lreatment was associated with significant improvements in over, 
all score, and in exertional fatigue, with evidence for benefit regardless of 
baseline severity. 
• Contrast ing Effects o f  Intravenous Dofeti l ide and 
Amlodarene on Cardiac Sympathetic Ol ive in 
Patients With Congest ive Heart Failure 
M,F. Rousseau, P.E. Massart, L. Galanti, S.A. Ahn. J. Etienne, 
H,G. Pouleur. University of Louvain. Brussels. Belgium 
In contrast o IV dofetilide (DOF, a pure IKr blocker), IV amiodamne (AMIO) 
lowers aortic presstlre and hence, could trigger bamreceptor eflex. To assess 
the implications of this sy'~temic effect of AMIO at the cardiac level, corenaw 
sinus (CS) ~,ow (thermodilution) and aortic and CS norepinephrine (NE) 
concentrations were measured in 30 pts with congestive heart failure (NYHA 
II-IIh LVEF: 19 i 8%). before and after a 30 min infusion of placebo (P; n = 
12). DOF (8/4g/kg; n = 12) or AMIO (5 mg/kg; n = 6). CS flow was little affected 
by infusions (Pc +3.6°/o; DOF: -4.0%; AMIO: +4.7%; all NS) and myocardial 
02 consumption decreased slightly with all drugs (Pc -1.0 mllmin; AMIO: 
-0.2: DOF: -1.6: all NS). AMIO alone significantly decreased dP/dt Max 
and mean aortic P (-9 mmHg *&) whereas only DOF prolonged single lead 
QT (+106 ms *& vs + 10 with AMIO and +9 with P). However, AMIO increased 
